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Hidradenitis suppurativa (HS)/acne inversa is a debilitating chronic disease that remains
poorly understood and di cult to manage. Clinical practice is variable, and there is a
need for international, evidence‐based and easily applicable consensus on HS
management. We report here the  ndings of a systematic literature review, which were
subsequently used as a basis for the development of international consensus
recommendations for the management of patients with HS. A systematic literature
review was performed for each of nine clinical questions in HS (de ned by an expert
steering committee), covering comorbidity assessment, therapy (medical, surgical and
combinations) and response to treatment. Included articles underwent data extraction
and were graded according to the Oxford Centre for Evidence‐based Medicine criteria.
Evidence‐based recommendations were then drafted, re ned and voted upon, using a
modi ed Delphi process. Overall, 5310 articles were screened, 171 articles were
analysed, and 65 were used to derive recommendations. These articles included six
randomized controlled trials plus cohort studies and case series. The highest level of
evidence concerned dosing recommendations for topical clindamycin in mild disease
(with systemic tetracyclines for more frequent/widespread lesions) and biologic therapy
(especially adalimumab) as second‐line agents (following conventional therapy failure).
Good‐quality evidence was available for the hidradenitis suppurativa clinical response
(HiSCR) as a dichotomous outcome measure in in ammatory areas under treatment.
Lower‐level evidence supported recommendations for topical triclosan and oral zinc in
mild‐to‐moderate HS, systemic clindamycin and rifampicin in moderate HS and
intravenous ertapenem in selected patients with more severe disease. Intralesional or
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systemic steroids may also be considered. Local surgical excision is suggested for mild‐
to‐moderate HS, with wide excision for more extensive disease. Despite a paucity of
good‐quality data on management decisions in HS, this systematic review has enabled
the development of robust and easily applicable clinical recommendations for
international physicians based on graded evidence.
Introduction
Hidradenitis suppurativa (HS)/acne inversa is a debilitating, chronic, in ammatory skin
disease that, for the most part, remains poorly understood and managed. The prevalence of
HS is estimated to be around 1% of the general population, it occurs more frequently in
females than males, and it usually presents after puberty.1 Keratin plugging of hair follicles
and recurrent in ammation lead to the formation of painful nodules and abscesses that
rupture, causing sinus tracts (tunnels) and scarring.1, 2 Patients often experience long
delays before an HS diagnosis is established.2 Moreover, the disease is often associated
with a signi cant negative impact on quality of life.2
Hidradenitis suppurativa is di cult to treat, and clinical practice is variable; therefore, there
remains a large unmet medical need in this area. Evidence‐based treatment guidelines for
HS are rare; the original S1 guidelines developed by the European Dermatology Forum,1 a
revised version including graded levels of evidence and  rst‐, second‐ and third‐line
treatment recommendations,2 and national guidance publications3-5 are some of the few
resources currently available. There is a need for international, evidence‐based consensus
on management of HS that is widely and easily applicable in clinical practice.
The aim of the HS ALLIANCE working group was to develop international consensus
recommendations for the treatment and management of patients with HS, which go beyond
the current guidelines and provide practical suggestions on how tools and treatments
should be used. The recommendations cover key areas identi ed by the International
Steering Committee (ISC) as imperative to address, including comorbid diseases, antibiotic
and biologic therapies, surgical interventions and monitoring.
Methods
HS ALLIANCE working group
The working group consists of an ISC of experts in the  eld of dermatology and
dermatologic surgery, bibliographic fellows (nominated by the ISC) and national faculty
members (known physicians with an interest in HS; Appendix S1). Together, they represent
25 countries worldwide.
The ISC identi ed a number of key areas for clinical focus in HS and de ned a list of clinical
questions that should be answered in order to develop consensus recommendations, using
a modi ed Delphi consensus process (Fig. 1). These questions were ranked and re ned by
the national faculty, clinical care gaps were identi ed, and a  nal list of nine overarching
questions was selected.
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Figure 1
Open in  gure viewer PowerPoint
Representation of the modi ed Delphi process used to reach consensus.
Caption 
To address these questions, systematic literature searches were performed by the
bibliographic fellows, supported by the ISC and a report containing draft evidence‐based
statements developed for review by the national faculty. Several hundred comments were
reviewed and incorporated by the ISC (assisted by the bibliographic fellows), and a  nal
consolidated report was prepared for the working group. The report was then discussed at
a face‐to‐face meeting (Copenhagen, Denmark, on 10 and 11 February 2017), at which the
group re ned and voted upon the draft recommendations.
Literature search
For each clinical question to be answered (nine in total), a bibliographic fellow performed a
systematic literature search. Search terms and strings were constructed and tested in
conjunction with the ISC. Search strings incorporated both Medical Subject Headings (MeSH)
and free text key words (Appendix S1). Databases searched include PubMed/Medline, The
Cochrane Library, EMBASE, CINAHL, SCOPUS, BIOSIS and Web of Science. Further manual
searches were conducted, as required, for recent abstracts, trial registries and relevant
articles from reference lists.
Included study designs comprised randomized controlled trials (RCTs), prospective and
retrospective studies, case series with ≥10 cases and other peer‐reviewed articles. Animal
studies, single case studies or case series with <10 patients, narrative reviews, editorials and
non‐peer‐reviewed articles were excluded. Studies considered had to be published between
August 1996 and the date of this review (August 2016), and be in English language.
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Identi ed articles underwent a two‐stage screening process:  rstly, titles and abstracts were
scanned for relevance to the clinical question being investigated, and secondly, full‐text
copies of relevant articles were obtained and reviewed against the inclusion and exclusion
criteria, and any duplicate, low‐quality or outdated articles were excluded.
Included articles had the following data extracted: study characteristics, including design,
setting/data source and study period; participant characteristics, such as sample size, mean
age, sex, mean follow‐up (if applicable) and location of the disease; baseline (pretreatment)
characteristics, where applicable; severity of HS and treatment history to assess
homogeneity within populations; treatment, where applicable, including type, dosage and
length of treatment; and outcomes after treatment, where applicable (de ned per
question).
Evidence was rated by the bibliographic fellows working on each clinical question
(individuals or pairs), using the Oxford Centre for Evidence‐based Medicine criteria
(http://www.cebm.net/index.aspx?o=1025). Data extraction and reporting were performed
according to the 2009 PRISMA statement (http://www.prisma-
statement.org/PRISMAStatement/PRISMAStatement.aspx) (Appendix S2).
Development of evidence‐based statements
A report summarizing the collected evidence was prepared for each question, including
evidence ratings and draft evidence‐based statements; this was reviewed by the ISC before
sending out to the national faculty for review. Each participating nation organized a local
faculty meeting, at which the faculty indicated their agreement with the draft statements,
discussed any concerns and suggested any wording amends. These discussions and
revisions were captured in a meeting report from each nation and were passed to the ISC
for review. The ISC considered all national faculty feedback and prepared a consolidated
report with revised statements for each clinical question. The consolidated report was sent
to the working group for review ahead of the international meeting, at which the ISC and
national faculty representatives voted on each evidence‐based statement.
Voting process
Individuals assigned each statement an ‘agreement score’ between 1 (lowest) and 9
(highest), and these scores were collated into one of three ranges: 1–3, 4–6 and 7–9. Level of
agreement was indicated by the percentage of individuals scoring within the 7–9 range; if
≥75% of individuals scored a statement within the 7–9 range, agreement was recorded. If no
agreement was achieved, the statements were discussed and amended with agreement
from the ISC co‐chairs, and voting took place again. If agreement was not achieved after a
second vote, a lack of agreement was recorded. One vote was allowed per country among
the national faculty members, and one vote for each member of the ISC.
Results
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In total, 5310 articles were screened and 171 were included in the data analysis. Very few
RCTs have been conducted in HS; therefore, many of the available data were from case
series or expert opinion (grade 4 or 5 evidence).
Assessment of comorbidities
Fewer than 20 articles were available to guide practice around assessment of comorbidities
in patients with HS; nonetheless, much of the available evidence was high grade (level 1 or
2). Recommendations on assessment of comorbid disorders in patients with HS are
presented in Table 1 and summarized below.
Table 1. Recommendations for assessment of comorbid disorders in patients with HS
What comorbidity‐related screening should be assessed in patients with HS?
Comorbidities and risk factors for HS include (evidence level, grade of recommendation):
Treatment of HS should include careful assessment of comorbid disorders and risk factors, referral for
appropriate diagnosis and treatment when needed and consideration of the impact of these factors on
HS treatment decisions. Pretreatment screening should be performed where necessary
Consensus
(93%)
Weight loss/reduction in body mass index (obese patient; BMI ≥ 30) can be e ective in reducing
severity of disease in the long term12, 16 (evidence level 4, grade of recommendation C).
Consensus
(100%)
Smoking (1, A)
Cardiovascular disease (2, B)
Metabolic syndrome (2, B)
Obesity (2, B)
Depression (3, B)
Diabetes mellitus (3, B)
Hypertension (3, B)
Hypertriglyceridemia (3, B)
Spondyloarthropathy (3, B)
Crohn's disease (4, C)
0%
range
1–3
7%
range
4–6
93%
range
7–9
0%
range
1–3
0%
range
4–6
100%
range
7–9
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What comorbidity‐related screening should be assessed in patients with HS?
When assessing patients, particular emphasis should be paid to psychological comorbidity18
(evidence level 5, grade of recommendation D).
Consensus
(100%)
In patients with chronic perianal and perineal HS, and in particular in the presence of  stulas, the
possibility of Crohn's disease should be considered21 (evidence level 5, grade of recommendation
D).
Consensus
(96%)
The potential for malignant transformation in patients with chronic HS should be recognized20
(evidence level 5, grade of recommendation D).
Consensus
(100%)
The association between HS and smoking is particularly strong, although a causal
relationship has not been ascertained. An increased risk of metabolic syndrome in HS is
recognized,6-9 with associated increases in risk for cardiovascular (CV) events and mortality;
notably, the risk of CV death is 58% higher in patients with HS than in patients with severe
psoriasis.10 Obesity is also a well‐established independent risk factor for HS,11-15 with
improvements in disease severity demonstrated after weight loss.12, 16, 17 Re ecting the
psychological and physical burden of the disease, rates of depression and anxiety among HS
patients are signi cantly increased compared with age‐ and gender‐matched controls.18
0%
range
1–3
0%
range
4–6
100%
range
7–9
4%
range
1–3
0%
range
4–6
96%
range
7–9
0%
range
1–3
0%
range
4–6
100%
range
7–9
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Other severe in ammatory conditions, such as Crohn's disease and spondyloarthropathy,
can co‐exist in HS patients.19 In addition, HS lesions can undergo malignant transformation
into squamous cell carcinoma. This is a rare occurrence, but is associated with a high
mortality rate.20
Nonetheless, an association with comorbidity does not infer a recommendation for
widespread screening in HS; clinicians should adhere to the latest population‐based
screening recommendations in distinct populations, e.g. screening for metabolic syndrome
in obese patients.
Treatment
Medical therapy
Apart from topical clindamycin and systemic tetracycline, the evidence for e cacy of non‐
biologic agents in HS comes from level 4 studies and expert opinion, including the previous
European S1 guidelines. The size and design of studies, as well as the absence of long‐term
data for non‐biologic treatments, make standardized recommendations on optimal
management challenging (Table 2).
Table 2. Recommendations for medical treatment of HS
Which non‐biologic therapies are e ective in the short, medium and long term for the treatment of HS?
There are very few long‐term data26, 33, 34 Consensus
(100%)
In Hurley stage II/III patients presenting with several active lesions, systemic clindamycin and rifampicin
(dosage: 300 mg twice daily) should be administered for an average length of 10 weeks24-27 (evidence
level 4, grade of recommendation C).Local antibiotic guidelines should be followed The S1 European
guidelines recommend that antibiotics should be used for up to 3 months and reintroduced in case of
recurrence under the requirement that they were e ective at the last time of use1 (evidence level 5,
grade of recommendation D)
Consensus
(100%)
[after
revote]
0%
range
1–3
0%
range
4–6
100%
range
7–9
0%
range
1–3
0%
range
4–6
100%
range
7–9
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Systemic acitretin may be considered as a third‐line therapy for patients with mild/moderate HS35-38
(evidence level 4, grade of recommendation C).
Consensus
(100%)
Which antibiotics are and are not e cacious for the treatment of HS and how should they be used?
In Hurley stage I/II patients with mild localized HS with few lesions, topical clindamycin 1% is a possible
therapy, especially in the absence of deep in ammatory lesions (abscesses).23 The topical formulation
may be administered twice daily for a maximum of 3 months. Resistance to clindamycin has changed
since reviewed studies were completed; therefore, local antibiotic guidelines should be followed
(evidence level 2, grade of recommendation B).
Consensus
(92%)
[after
revote]
In Hurley stage I/II patients presenting with several lesions and frequent exacerbations, the therapeutic
group of systemic tetracyclines may be considered23 (evidence level 2, grade of recommendation
B).However, many countries use other derivatives from the same group (e.g. doxycycline, minocycline),
for which there is no high‐level evidence. Only one antibiotic of the same class should be used for a
maximum of 12 weeks. Local antibiotic guidelines should be followed.
Consensus
(100%)
In Hurley stage II/III patients presenting with several active lesions, systemic clindamycin and rifampicin
(dosage: 300 mg twice daily) should be administered for an average length of 10 weeks24-27 (evidence
level 4, grade of recommendation C).Local antibiotic guidelines should be followed.
Consensus
(96%)
0%
range
1–3
0%
range
4–6
100%
range
7–9
0%
range
1–3
8%
range
4–6
92%
range
7–9
0%
range
1–3
0%
range
4–6
100%
range
7–9
0%
range
1–3
4%
range
4–6
96%
range
7–9
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A triple regimen of rifampicin (10 mg/kg once daily), moxi oxacin (400 mg once daily) and
metronidazole (500 mg thrice daily) administered for up to 12 weeks, with metronidazole
discontinuation at week 6, may o er e cacy in Hurley stage I and II patients, but should be used with
appropriate monitoring39 (evidence level 4, grade of recommendation C).Local antibiotic guidelines
should be followed.
Consensus
(81%)
In selected patients with severe HS, a 6‐week course of intravenous ertapenem (1 g daily) with
consolidation treatment of rifampicin/moxi oxacin/metronidazole may be considered40 (evidence
level 4, grade of recommendation C).Local antibiotic guidelines should be followed.
Consensus
(88%)
Antibiotics studied in HS (evidence level, grade of recommendation): Consensus
(96%)
There is no evidence for the use of other antibiotics Consensus
(100%)
The S1 European guidelines recommend that antibiotics should be used for up to 3 months and
reintroduced in case of recurrence under the requirement that they were e ective at the last time of
use1 (evidence level 5, grade of recommendation D).
Consensus
(100%)
0%
range
1–3
19%
range
4–6
81%
range
7–9
0%
range
1–3
12%
range
4–6
88%
range
7–9
Topical clindamycin 1% (2, B)
Systemic tetracyclines (2, B)
Combination therapy of systemic clindamycin and rifampicin (4, C)
Triple regimen of rifampicin, moxi oxacin and metronidazole (single study) (4, C)
Intravenous ertapenem (single study) (4, C)
Systemic dapsone (single study)41 (4, C)
0%
range
1–3
4%
range
4–6
96%
range
7–9
0%
range
1–3
0%
range
4–6
100%
range
7–9
0%
range
1–3
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In HS, microbiological cultures are not useful (evidence level 5, grade of recommendation D) Consensus
(92%)
How and when in the disease course of HS should biologics be introduced?
There are few RCTs and little high‐quality evidence Consensus
(100%)
Adalimumab should be considered as  rst‐choice biologic agent in moderate/severe HS after failure of
conventional treatments28-30 (evidence level 2, grade of recommendation B).
Consensus
(100%)
In iximab has also been shown to be e ective and should be considered as a second‐line biologic for
moderate/severe HS31 (evidence level 2, grade of recommendation B).
Consensus
(81%)
0%
range
4–6
100%
range
7–9
0%
range
1–3
8%
range
4–6
92%
range
7–9
0%
range
1–3
0%
range
4–6
100%
range
7–9
0%
range
1–3
0%
range
4–6
100%
range
7–9
4%
range
1–3
15%
range
4–6
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Anakinra (evidence level 2, grade of recommendation B) has also been shown to be e ective and
should be considered as a third‐line biologic for moderate/severe HS32 Ustekinumab (evidence level
4, grade of recommendation C) is a potentially e ective treatment for moderate/severe HS42
Consensus
(84%)
Etanercept is not e ective for the treatment of HS43 (evidence level 2, grade of recommendation B). Consensus
(96%)
When should (any) combinations of medical treatments be considered for patients with HS and what
combinations should be used?
Evidence for the use of combination therapy in HS is limited Consensus
(92%)
In Hurley stage II/III patients presenting with several active lesions, systemic clindamycin and rifampicin
(dosage: 300 mg twice daily) should be administered for an average length of 10 weeks24-27 (evidence
level 4, grade of recommendation C).Local antibiotic prescribing guidelines should be followed.
Consensus
(100%)
[after
revote]
81%
range
7–9
4%
range
1–3
12%
range
4–6
84%
range
7–9
0%
range
1–3
4%
range
4–6
96%
range
7–9
0%
range
1–3
8%
range
4–6
92%
range
7–9
0%
range
1–3
0%
range
4–6
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A triple regimen of rifampicin (10 mg/kg once daily), moxi oxacin (400 mg once daily) and
metronidazole (500 mg thrice daily) administered for up to 12 weeks, with metronidazole
discontinuation at week 6, may o er e cacy in Hurley stage I and II patients, but should be used with
appropriate monitoring39 (evidence level 4, grade of recommendation C).Local antibiotic
prescribing guidelines should be followed.
Consensus
(100%)
[after
revote]
In Hurley stage I/II, the combination of oral zinc gluconate (30 mg thrice daily) and topical triclosan 2%
(twice daily) may be considered as a treatment option44 (evidence level 4, grade of
recommendation C).
Consensus
(81%)
Intralesional steroids may be helpful for acute in ammatory nodules in combination with other
treatments at all Hurley stages45 (evidence level 4, grade of recommendation C).
Consensus
(80.8%)
Low‐dose systemic corticosteroids (10 mg prednisolone equivalent per day) may be an e ective
adjunct in recalcitrant HS46 (evidence level 4, grade of recommendation C).Long‐term corticosteroid
treatment should be used with appropriate caution.
Consensus
(96%)
100%
range
7–9
0%
range
1–3
0%
range
4–6
100%
range
7–9
0%
range
1–3
19%
range
4–6
81%
range
7–9
11.5%
range
1–3
7.7%
range
4–6
80.8%
range
7–9
0%
range
1–3
4%
range
4–6
96%
range
7–9
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The evidence‐based literature available on the use of antibiotics in HS is limited and largely
restricted to retrospective studies. The combination of systemic clindamycin and rifampicin
is by far the most investigated treatment. For Hurley stage I/II, topical clindamycin 1% is a
possible therapy, especially in the absence of abscesses.22, 23 If there are several lesions
and frequent exacerbations, the therapeutic group of systemic tetracyclines may be
considered.23 A triple regimen of rifampicin (10 mg/kg once daily), moxi oxacin (400 mg
once daily) and metronidazole (500 mg thrice daily) administered for up to 12 weeks, with
metronidazole discontinuation after 6 weeks, may be an alternative option. In Hurley stage
II/III patients who have several active lesions, systemic clindamycin and rifampicin (dosage:
300 mg twice daily) should be administered.24-27
Six RCTs assessing the use of biologic therapy have been performed to date in HS (four of
them with adalimumab), and two more are ongoing. Recommendations for the use of these
agents are based on the results of these trials. Adalimumab should be considered as the
 rst‐choice biologic agent in moderate/severe HS after failure of conventional
treatments,28-30 followed by in iximab31 and anakinra32 as second‐ and third‐line
options, respectively.
Evidence for combination therapies is very limited and largely focused on small case series
or retrospective reviews of antibiotics, topical triclosan and oral zinc or steroid‐based
therapies.
Surgical therapy
The evidence for surgical therapies in HS is based on case series and cohort studies with
di ering methodologies and outcome de nitions (low‐grade evidence; Table 3).
Table 3. Recommendations for surgical treatment of HS
Which types of surgery may bene t patients with HS?
Case and cohort studies used variable de nitions of recurrence and a wide range of follow‐up time
and, therefore, cannot be compared.
Consensus
(100%)
In acute situations, surgical incision and drainage of tense and painful abscesses, i.e.  uctuant lesions,
may be performed. However, incision and drainage should not be considered as a sole treatment
Consensus
(100%)
0%
range
1–3
0%
range
4–6
100%
range
7–9
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because recurrence is almost inevitable47-50 (evidence level 4, grade of recommendation C).
Surgical procedures, such as limited excision, deroo ng and STEEP, can be used for solitary lesions of
the disease. They could be performed for recurrent HS lesions at  xed locations or  stula/sinus tract
formation in limited areas51 (evidence level 4, grade of recommendation C).
Consensus
(100%)
Wide excision of the entire a ected area, with removal of (non‐)in amed sinuses, nodules and scar
tissue, may be performed in Hurley stage III to prevent recurrence53-55 (evidence level 4, grade of
recommendation C).
Consensus
(96%)
Chronic HS lesions that have not shown any signs of in ammation for a prolonged period of time may
be excised to prevent further recurrence56, 57 (evidence level 5, grade of recommendation D).
Consensus
(78%)
Special attention should be paid to patients with perianal and/or perineal HS due to the possible
existence of anal, urethral and vaginal  stulas and presence of squamous cell carcinoma47, 58
(evidence level 4, grade of recommendation C).
Consensus
(92.6%)
0%
range
1–3
0%
range
4–6
100%
range
7–9
0%
range
1–3
0%
range
4–6
100%
range
7–9
0%
range
1–3
4%
range
4–6
96%
range
7–9
7%
range
1–3
15%
range
4–6
78%
range
7–9
3.7%
range
1–3
3.7%
range
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CO  ablative laser treatment is an e ective alternative method to electrosurgical or cold steel
techniques59, 60 (evidence level 4, grade of recommendation C).
Consensus
(100%)
How should medical and surgical treatments be integrated?
There are no RCTs describing the combination of medical and surgical treatments Consensus
(92.6%)
Pre‐ and postoperative biologic therapy may lead to a lower recurrence rate and a longer disease‐free
interval61, 62 (evidence level 4, grade of recommendation C).
Consensus
(89%)
There is no current literature regarding adverse events when integrating biologic therapy and surgery
in HS patients. Studies in other immune‐mediated diseases are insu cient to advise preoperative
interruption of biologics (evidence level 5, grade of recommendation D).
Consensus
(100%)
4–6
92.6%
range
7–9
2
0%
range
1–3
0%
range
4–6
100%
range
7–9
3.7%
range
1–3
3.7%
range
4–6
92.6%
range
7–9
0%
range
1–3
11%
range
4–6
89%
range
7–9
0%
range
1–3
0%
range
4–6
100%
range
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Adalimumab reduces the need for surgical procedures (incisions and drainage)29 (evidence level 2,
grade of recommendation C).
Consensus
(85.7%)
The type of surgery performed and the required margins are based on the severity of the
disease.1 For limited disease with solitary lesions, individual abscesses may be drained as a
supplemental measure,47-50 and surgical procedures, such as limited excision, deroo ng
and STEEP, can be performed.51 For tense and painful abscesses, no medical therapy will
be e ective and surgical drainage may be required;52 however, this should not be
considered as sole treatment, because recurrence is almost inevitable. Widespread, severe
disease requires more extensive excision.53-55 Chronic inactive lesions can be removed to
prevent recurrence.56, 57
There is limited evidence for the combination of medical and surgical therapies in HS.
Studies in other immune‐mediated diseases (psoriasis, psoriatic arthritis, rheumatoid
arthritis and in ammatory bowel disease) are insu cient to advise on preoperative
interruption of biologics (Appendix S1).
Monitoring disease activity and response to therapy
Within the 13 RCTs performed in patients with HS, 90% of the outcome measures lacked
validated data to support their clinical applicability. Seven studies of six di erent HS
outcome measures have provided validation data;11, 14, 63-67 however, one measure [the
acne inversa severity index (AISI)]64 is yet to be employed in an RCT. Hurley stage
measurements and Sartorius scoring are widely used assessments of severity; however,
these have limitations and are only partially validated.14, 63, 67 Validated outcome
measures that may be used to assess changes in disease over time or following treatment
include the hidradenitis suppurativa clinical response (HiSCR),66 which is supported by
good‐quality evidence, and more general measures encompassing physician‐ and patient‐
reported levels of extent, pain and quality of life.11, 64, 65
High‐level trial data for use of adalimumab in patients with HS suggest that those patients
who do not respond to treatment (<25% improvement in abscesses and in ammatory
nodules) within 12 weeks should discontinue the drug, while partial or good responders
should continue the therapy with ongoing assessment.28, 29, 68, 69 Evidence is lacking for
7–9
3.6%
range
1–3
10.7%
range
4–6
85.7%
range
7–9
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other biologic therapies, and any clinical decisions should be based on close monitoring and
risk : bene t assessments.
The working group recommendations for assessment of disease and monitoring are given
in Table 4.
Table 4. Recommendations for assessment of disease and monitoring
How should disease activity and response to treatment be monitored in patients with HS?
The majority of the outcome measurement instruments used in HS RCTs lack substantial validation
evidence. Furthermore, a validated measure for baseline severity assessment is also unexplored. This
may hamper comparisons of HS trials investigating future treatment regimens
Consensus
(100%)
Hurley staging is suggested by experts for assessment of baseline severity, especially with regard to
the extent of scarring. It is, however, not a dynamic tool and so it should only be used to describe an
area a ected by HS (and not to de ne overall severity of disease). Each individual area a ected by HS
should be assessed independently (evidence level 5, grade of recommendation D).
Consensus
(96%)
The HiSCR is supported by good‐quality validation studies and is recommended to be used as a
dichotomous outcome measure in in ammatory areas under treatment66 (evidence level 2, grade of
recommendation B).
Consensus
(100%)
Patient‐reported outcome measures (e.g. DLQI, VAS) should be included in the overall assessment of
the HS patient as they may o er important insight on functioning, quality of life and symptoms (e.g.
pain and itching)63, 64 (evidence level 4, grade of recommendation C).
Consensus
(100%)
0%
range
1–3
0%
range
4–6
100%
range
7–9
0%
range
1–3
4%
range
4–6
96%
range
7–9
0%
range
1–3
0%
range
4–6
100%
range
7–9
0%
range
1–3
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The modi ed Sartorius score has been partially validated and can be used to assess severity14, 67
(evidence level 4, grade of recommendation C).
Consensus
(96%)
How long should biologics be used in patients responding/not responding?
Adalimumab28, 29, 68, 69: Consensus
(92.6%)
Not enough published data are available for other biologics. Decisions about whether and how to
continue treatment should be based on a close monitoring of patients and careful assessment of the
risk : bene t ratio (evidence level 5, grade of recommendation D).
Consensus
(96%)
DLQI, dermatology life quality index; VAS, visual analogue scale.
0%
range
4–6
100%
range
7–9
0%
range
1–3
4%
range
4–6
96%
range
7–9
In patients with <25% improvement in abscess and in ammatory nodule [AN] count after 12 weeks,
treatment with adalimumab should not be continued (evidence level 2, grade of
recommendation B).
For patients who do not achieve HiSCR, but achieve a 25–50% improvement in AN count (partial
response) after 12 weeks, consider continuing treatment and re‐evaluate after an additional 3
months (evidence level 2, grade of recommendation B).
In the short term, studies show recurrence following discontinuation of treatment after 11–12
weeks (evidence level 4, grade of recommendation C).
Long‐term (at least 1 year) continuous treatment maintains a level of consistent e ectiveness in
patient responders (evidence level 2, grade of recommendation B).
3.7%
range
1–3
3.7%
range
4–6
92.6%
range
7–9
0%
range
1–3
4%
range
4–6
96%
range
7–9
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This systematic literature review demonstrates the paucity of an evidence base for clinical
decision‐making in HS. This is both in terms of the number of studies and the quality of the
data (Appendix S3). The highest level evidence available addresses the use of topical and
systemic antibiotics and biologic therapies, especially adalimumab. The majority of the
remaining evidence to guide management decisions is based on case reports, small cohort
studies and expert opinion. The dearth of high‐quality evidence in HS strengthens the need
for practical expert consensus recommendations to optimize management worldwide and
improve care for these patients. The HS ALLIANCE of international experts has reviewed the
available data and has developed these consensus clinical recommendations that are both
pragmatic and evidence‐based.
Only 13 RCTs have been performed in HS; of these, seven have not formed the basis of
treatment recommendations made in this review. This is due to the inclusion criteria of the
review, and limited clinical applicability or patient numbers (see Appendix S1 for details).
Intense pulsed light and photodynamic therapy studies provide limited data for the
treatment of HS. Their applicability to widespread practice and outcomes is currently
unknown. Further research is warranted for these promising supplemental therapies.
Topical clindamycin may be used in early HS; however, real‐world resistance to clindamycin
tends to be higher than suggested in a RCT, and the e cacy of topical clindamycin Hurley
stage II is questioned by many physicians. Systemic tetracyclines are an alternative option,
but these are no longer available in some countries. The combination of 100 mg
minocycline administered orally once per day and 0.5 mg colchicine administered twice per
day for 6 months, followed by maintenance 0.5 mg colchicine for 3 months, has recently
been shown to provide substantial improvement or remission in a prospective pilot study in
20 patients;70 further investigation of this combination is warranted. For Hurley stage II/III
HS, the use of systemic antibiotic combinations is common, despite there being only low‐
grade (level 4) evidence to support this. Furthermore, the US Food and Drug Administration
has recommended that  uoroquinolone antibiotics be reserved for patients with acute
infections who have no alternative treatment options, due to a poor risk : bene t pro le
(https://www.fda.gov/Drugs/DrugSafety/ucm500143.htm). Long‐term use of any antibiotic is
not recommended.
The use of intravenous ertapenem is included in this review as a treatment option in
selected severe patients, but its use is at the discretion of the treating physician; the study
on which this recommendation is based included patients who were not surgical
candidates, or who had been refused a surgical intervention.40 This study was given the
same grading as the evidence for systemic clindamycin and rifampicin;24-27 however, the
working group considered the recommendation for ertapenem to be less strong.
Adalimumab is considered the  rst‐line biologic therapy in HS due to the amount of high‐
level evidence available to support its use. The indicated dose of adalimumab in HS is 160
mg on day 1, 80 mg on day 15 and a single 40 mg injection every week from week 4
onwards. This is a higher dosing schedule than that for plaque psoriasis, in which the
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recommended regimen is 80 mg on day 1, 40 mg on day 8 and 40 mg every other week
thereafter. In iximab also has high‐level evidence to support its use; nonetheless, the
primary outcome of the RCT investigating in iximab was neither validated nor achieved. The
dosing schedule for in iximab is 5 mg/kg body weight on day 0, 2 and 6 and then every 8
weeks. Anakinra was considered by the group as third‐line, despite having the same grade
of evidence as in iximab; this was due to the study including fewer patients and di erent
outcomes. Also, earlier studies of anakinra had been less convincing than those for
in iximab. Case reports of etanercept suggest e cacy in HS; however, the performed RCT
showed no e ect, and our recommendation is based on this high‐level evidence.
Secukinumab was not included in these recommendations due to lack of evidence at the
time of the literature search; however, a pilot study for this drug in HS is now underway
(ClinicalTrials.gov Identi er: NCT03099980).
Many physicians managing HS routinely collect blood and skin samples to assess bacterial
cultures and treat their patients according to the results. Traditional microbiological
sampling is not useful in HS and should not in uence treatment decisions, as there is no
evidence for infection as a causal factor. Antibiotics are prescribed in HS for their anti‐
in ammatory properties, rather than for their antibacterial action; this may be an essential
point for physicians in their understanding of the pathogenesis of HS. Likewise, antiseptics
are commonly prescribed with no evidence base to support their use, except for reducing
smell.
The modi ed Sartorius score (MSS) has been partially validated as a tool to assess disease
severity; however, it can be considered time‐consuming to use, and several versions of this
score have been developed with inconsistent use of terminology, leading to confusion
among physicians. For example, modi ed HS score (modi ed HSS), MSS and HS‐LASI (HS
lesion, area and severity index) are all used.14, 29, 71, 72 The HiSCR has more validation
data than other traditional severity tools; however, a further validated tool to assess cross‐
sectional severity in HS has recently been developed.73
The HS ALLIANCE working group highlighted a number of future research topics for HS
during consensus discussions. Foremost, the group felt that new RCTs investigating
individual or combination therapies for HS were needed and that these should include
appropriate and validated outcome measures, patient‐reported outcomes and long‐term
data. The e ect of treatments for HS on associated CV risk factors was also an area of
potential interest, especially considering that use of metformin and anti‐TNF‐alpha agents in
other diseases has been associated with reduced CV risk.74, 75 Evidence to guide optimal
practice for integrating medical and surgical therapies is also required, along with further
validation of outcome measures to assess changes in HS activity over time and with
treatment response.
The paucity of high‐level evidence on which to base clinical recommendations, especially
regarding optimal treatment strategies for long‐term and CV outcomes, was a limitation to
this systematic review. Furthermore, multiple literature reviewers were involved, meaning
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that despite the same objectives and criteria, slight di erences occurred in the way the
search strings were designed and the data reviews were executed. Due to the design of the
consensus process, the literature searches were performed in advance of the
recommendations being  nalized and this review being written; therefore, some of the
latest evidence, including preliminary studies of spironolactone, ustekinumab and
apremilast, was not considered within the recommendations. We would recommend that an
update to these recommendations and evidence grades is performed once ongoing RCTs
have reported, including any additional data that were not captured here.
The HS ALLIANCE recommendations in this review largely agree with the current clinical
practice guidelines in Europe,1, 2 suggesting similar approaches for  rst‐ and second‐line
medical and surgical treatment options (Appendix S1; comparison of current
recommendations). The German guidelines and the recent Swiss and Canadian guidance3-5
incorporated existing evidence and practitioners’ expertise into a framework for the
evaluation and treatment of patients with HS, in a non‐systematic fashion. Nonetheless, the
discussed medical and surgical therapies align with those in the European S1 guidance,
albeit with a greater focus on hormonal and laser therapies in Canada. The original
European S1 guideline1 and the German and Swiss guideline o ered no methodology for
creation of the recommendations, but declared funding and con ict of interests from the
guideline groups. Building on these, Gulliver et al.2 reviewed and graded the available
evidence behind the therapeutic recommendations and created an algorithm for
management of HS, while providing more transparent methodology and less con ict
information. The current guidelines employed both a systematic, consensus approach and a
high level of transparency to generate recommendations that address previously
unanswered questions in clinical practice and are clear to implement. A summary of the
guideline ratings is available in the Appendix S1.
In conclusion, there is currently a paucity of research evidence available for HS, in terms of
numbers of studies and quality of data. Nonetheless, this systematic literature review
captures and grades the available evidence in order to provide applicable recommendations
on important clinical questions for healthcare professionals managing HS. The current
international guidance goes beyond the regional recommendations available, providing a
comprehensive and transparent set of consensus guidelines for HS.
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